These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19722166)

  • 1. Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats.
    Barve A; Chen C; Hebbar V; Desiderio J; Saw CL; Kong AN
    Biopharm Drug Dispos; 2009 Oct; 30(7):356-65. PubMed ID: 19722166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of dietary kaempferol and its metabolite 4-hydroxyphenylacetic acid in rats.
    Zabela V; Sampath C; Oufir M; Moradi-Afrapoli F; Butterweck V; Hamburger M
    Fitoterapia; 2016 Dec; 115():189-197. PubMed ID: 27810397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic evaluation of the interaction between oral kaempferol and ethanol in rats.
    Zhou Z; Wang M; Guo Z; Zhang X
    Acta Pharm; 2016 Dec; 66(4):563-568. PubMed ID: 27749255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats.
    Li C; Li X; Choi JS
    Arch Pharm Res; 2009 Jan; 32(1):133-8. PubMed ID: 19183886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats.
    Piao Y; Shin SC; Choi JS
    Biopharm Drug Dispos; 2008 May; 29(4):245-9. PubMed ID: 18338336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of kaempferol to increase bioavailability and pharmacokinetics of nifedipine in rats.
    Park JW; Choi JS
    Chin J Nat Med; 2019 Sep; 17(9):690-697. PubMed ID: 31526504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of ethylene glycol. III. Plasma disposition and metabolic fate after single increasing intravenous, peroral, or percutaneous doses in the male Sprague-Dawley rat.
    Frantz SW; Beskitt JL; Tallant MJ; Zourelias LA; Ballantyne B
    Xenobiotica; 1996 May; 26(5):515-39. PubMed ID: 8736063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats.
    Han KS; Kim YG; Yoo JK; Lee JW; Lee MG
    Biopharm Drug Dispos; 1998 Nov; 19(8):493-500. PubMed ID: 9840211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-independent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
    Lee MH; Bae SK; Kim EJ; Kim YG; Kim SO; Lee DH; Lim H; Yoo SE; Lee MG
    J Pharm Sci; 2003 Jan; 92(1):190-201. PubMed ID: 12486695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of amitriptyline and one of its metabolites, nortriptyline, in rats: little contribution of considerable hepatic first-pass effect to low bioavailability of amitriptyline due to great intestinal first-pass effect.
    Bae SK; Yang KH; Aryal DK; Kim YG; Lee MG
    J Pharm Sci; 2009 Apr; 98(4):1587-601. PubMed ID: 18780336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
    Kim SH; Lee MG
    Life Sci; 2002 Feb; 70(11):1299-315. PubMed ID: 11883708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of dietary cancer chemopreventive compound dibenzoylmethane in rats and the impact of nanoemulsion and genetic knockout of Nrf2 on its disposition.
    Lin W; Hong JL; Shen G; Wu RT; Wang Y; Huang MT; Newmark HL; Huang Q; Khor TO; Heimbach T; Kong AN
    Biopharm Drug Dispos; 2011 Mar; 32(2):65-75. PubMed ID: 21341276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of kaempferol on the pharmacokinetics of nifedipine in rats].
    Xu M; Yang M; Zheng YF; Zhu HJ; Zhu XQ
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 35(1):23-8. PubMed ID: 16470916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
    Shim HJ; Kim YC; Park KJ; Kim DS; Kwon JW; Kim WB; Lee MG
    J Pharm Sci; 2003 Nov; 92(11):2185-95. PubMed ID: 14603504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences.
    Roller S; Cui D; Laspina C; Miller-Stein C; Rowe J; Wong B; Prueksaritanont T
    Xenobiotica; 2009 Jan; 39(1):33-45. PubMed ID: 19219746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Exposure of Kaempferol Is Driven by Phase II Metabolic Enzymes and Efflux Transporters.
    Zheng L; Zhu L; Zhao M; Shi J; Li Y; Yu J; Jiang H; Wu J; Tong Y; Liu Y; Hu M; Lu L; Liu Z
    AAPS J; 2016 Sep; 18(5):1289-1299. PubMed ID: 27393480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.